MDX-1097
MDX-1097
MDX-1097 (pronunciation: /ɛm diː ɛks 1097/) is a monoclonal antibody designed for the treatment of multiple myeloma. It is developed by Medarex, a biopharmaceutical company specializing in the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases.
Etymology
The term MDX-1097 is a proprietary name given by the company Medarex. The prefix 'MDX' stands for Medarex, and '1097' is a unique identifier for this specific antibody.
Mechanism of Action
MDX-1097 targets a specific protein found on the surface of multiple myeloma cells, known as BCMA (B-cell maturation antigen). By binding to this protein, MDX-1097 can help the immune system recognize and destroy the cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Multiple Myeloma: A type of blood cancer that begins in the plasma cells, a type of white blood cell.
- Medarex: A biopharmaceutical company that develops antibody-based therapeutics.
- BCMA (B-cell maturation antigen): A protein that is found on the surface of certain types of cancer cells, including multiple myeloma cells.
See Also
External links
- Medical encyclopedia article on MDX-1097
- Wikipedia's article - MDX-1097
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski